课题基金 / 基金详情

Mitophagy in pulmonary hypertension: Novel roles of PTEN-Induced Kinase-1 in the pathobiology of pulmonary artery smooth muscle cell proliferation and mitochondrial dysfunction

Mitophagy in pulmonary hypertension: Novel roles of PTEN-Induced Kinase-1 in the pathobiology of pulmonary artery smooth muscle cell proliferation and mitochondrial dysfunction
肺动脉高压中的线粒体自噬:PTEN 诱导的激酶 1 在肺动脉平滑肌细胞增殖和线粒体功能障碍病理学中的新作用
批准号:
10266041
负责人:
C MICHAEL HART
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-01 至 2023-06-30
关键词:
AffectApoptosisApoptoticAutophagocytosisBinding SitesBiologicalBiologyBlood flowCell ProliferationChronicChronic Obstructive Airway DiseaseChronic lung diseaseComplicationCoupledCyclic AMP-Responsive DNA-Binding ProteinDataDetectionDevelopmentDiseaseExhibitsExposure toFailureGene Expression RegulationGeneticGenetic TranscriptionGenus HippocampusGlycolysisGoalsHospital CostsHospitalizationHypoxemiaHypoxiaImaging TechniquesImpairmentIn VitroLeadLength of StayLuciferasesLungLung diseasesMediatingMetabolicMetabolismMicroRNAsMitochondriaMolecularMorbidity - disease rateMusOxygen ConsumptionPTEN genePTEN-induced putative kinasePathogenesisPathogenicityPathway interactionsPatientsPhenotypePhosphotransferasesPost-Transcriptional RegulationPredispositionPrognosisProliferatingProtein phosphatasePulmonary HypertensionPulmonary artery structureQuality ControlRattusRegulationReporterReportingResearchResearch Project GrantsRespirationRiskRodentRodent ModelRoleSignal TransductionSmooth Muscle MyocytesSourceStructure of parenchyma of lungTalentsTechniquesTestingTherapeuticTissuesTranscriptional RegulationTransfectionTransgenic MiceTransgenic OrganismsTumor Suppressor ProteinsVascular DiseasesVascular remodelingVentricularVeteransWorkbasebioinformatics toolcancer cellcellular imagingcomorbiditydifferential expressiondiminished oxidative phosphorylationexercise capacityexposed human populationhuman tissueimprovedimproved functioningin silicoin vivoinnovationinsightloss of functionlung hypoxiamilitary veteranmitochondrial dysfunctionmortalityneuroblastoma cellnew therapeutic targetnovelnovel therapeutic interventionpromoterpulmonary arterial hypertensionreduce symptomssmoking-related lung diseasetranscription factortranslational impactvector

项目摘要

项目成果

C MICHAEL HART的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pulmonary hypertension (PH) is a progressive disorder associated with a variety of diseases commonly afflicting veteran patients. Emerging evidence demonstrates that PH and excessive proliferation of pulmonary artery smooth muscle cells (PASMC) are caused by derangements in mitochondrial function that impair mitochondrial respiration and alter mitochondrial metabolic programming in a manner that enhances glycolytic metabolism and diminishes oxidative phosphorylation. However, abnormalities in mitochondrial quality control mechanisms that regulate mitophagy have not been investigated as a source of mitochondrial dysfunction and PASMC hyperproliferation in PH, and will be explored in detail in the proposed studies. The proposed studies will investigate the role of the mitophagy initiator protein, PTEN-induced putative kinase-1 (PINK1) in the pathogenesis of PH and PASMC proliferation. Our preliminary data demonstrate that PINK1 is reduced in hypoxia-exposed PASMC in vitro and in the lungs and pulmonary artery tissues of rodents that develop PH in hypoxic conditions. In the proposed studies, we will investigate the hypothesis that loss of PINK1 causes impairments in mitophagy and mitochondrial metabolic programming that lead to excessive PASMC proliferation in PH. Additional studies will define the mechanisms that regulate PINK1 loss in hypoxic conditions. We will test our hypothesis through the execution of the following Specific Aims: Aim 1 will investigate transcriptional and posttranscriptional mechanisms that regulate PINK1 through microRNA (miR). Among several miRs identified by in silico analysis, miR-27a and miR-516a exhibited the greatest differential expression changes in the hypoxic rodent lung and in hypoxic PASMC. Therefore, initial studies will determine if PINK1 loss occurs through miR-27a- or miR-516a-mediated posttranscriptional suppression of PINK1. To identify factors that regulate PINK1 transcription, we employed bioinformatics tools to define predicted transcription factor (TF) binding sites in the PINK1 promoter. Among several TFs identified, regulatory interactions between cAMP response element-binding protein (CREB) and PINK1 had not been previously validated. Therefore, we will conduct studies using a PINK1 promoter luciferase reporter vector to determine whether putative CREB binding sites are functional. To enhance the translational impact, we will determine mechanisms that regulate PINK1 expression and activity using idiopathic pulmonary artery hypertension (IPAH) PASMC and lung tissue. Aim 2 will characterize the functional consequences of PINK1 alterations on mitochondrial metabolic reprogramming, mitophagy, and PASMC proliferation in PH. In isolated rat PASMC, the impact of hypoxia or PINK1 gain and loss of function on mitochondrial oxygen consumption and glycolysis will be analyzed using the Seahorse XF96 Bioanalyzer™. Additional studies will determine the effects of hypoxia or PINK1 alterations on mitophagy in the lung in vivo using Mt-Keima transgenic mice and in PASMC isolated from rats and IPAH donors using the mKeima-Red® mitophagy detection vector in vitro. The fundamental goals of this proposal are to provide novel insights into aspects of mitochondrial dysfunction in PH that contribute to PASMC hyperproliferation and PH through alterations in PINK1 and mitophagy. The successful execution of this work will broaden our understanding of the role of mitophagy in PH and lay the groundwork to investigate novel therapies that target PINK1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms and Consequences of Reduced PPAR gamma in Pulmonary Hypertension
  • 批准号:
    8440548
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    C MICHAEL HART
  • 依托单位:
Mechanisms and Consequences of Reduced PPAR gamma in Pulmonary Hypertension
  • 批准号:
    8598800
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    C MICHAEL HART
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: